Hemifacial Spasm Market Analysis 2019 Key News by Top Companies with Latest Technology, Developments, Revenue, Size and Industry Growth Insights to 2023
Hemifacial
Spasm Market report analysis is done by experts which gives in-depth detail
information about the Hemifacial Spasm
Market industry segmentation, regional data & industry key players.
Hemifacial
Spasm Market Overview
Hemifacial spasm (HFS) is a disorder related to the
nervous system in which the muscles on either side of the face twitch
involuntarily, this is usually caused by a blood vessel touching a facial
nerve. It is a neuromuscular disorder characterized by frequent, involuntary
contractions of muscles on the face.
There are a number of novel treatments available to
treat this disorder including surgery, botulinum toxin (botox) injections,
acupuncture, and medications among others that are delivering exceptional
outcomes in relaxing the facial muscles.The spreading awareness towards the
availability of the HFS treatment is a key driving force behind the
exponentially growing hemifacial spasm market. Moreover, the successful
discoveries of many novel medicines and therapeutics to treat hemifacial spasm
are simultaneously, escalating the market on the global platform.
Additional factors encouraging the market growth
include increasing incidences of facial chorea and craniofacial tremor, unmet
medical needs, improving regulatory framework, increasing government
assistance, increasing adoption rate, and rising funding and reimbursement.
Global Hemifacial Spasm Market – Segments
The MRFR analysis is segmented into four key dynamics
for enhanced understanding.
By Diagnosis : Magnetic Resonance Imaging (MRI),
Computed Tomography (CT or CAT scan), and Angiography among others.
By Treatment : Medical Treatment, Surgical
Treatment, Combinational Therapy, Transcutaneous Electric Nerve Stimulation
(TENS) Therapy, and Physical Therapy among others.
By End-user : Hospitals, Clinics, Diagnostic Centers,
Drug Stores, and Pharmacies among others.
By Regions : North
America, Asia Pacific, Europe, and the Rest-of-the-World.
Hemifacial Spasm Market – Regional Analysis
The North American region, heading with rising
technological advancements and high healthcare expenditure accounts for the
leading market for hemifacial spasm treatment. Factors such as the
Presence of major medical device manufacturers, pharmaceutical companies, and
well-developed healthcare industry positively impacts the growth of the
regional market.
Technological advancements in the burgeoning
healthcare industry are providing new effective drugs for treatments that can
give better outcomes, and this is one of the key factors driving the growth of
the regional market. Furthermore, the rising awareness about the availability
of treatments for hemifacial spasm and the availability of emergency diagnostic
services foster the market growth in the region.
The hemifacial spasm market in the European region
holds the next largest share in the global market, owing to the resurging
economy that is availing the best possible healthcare and increasing the
healthcare expenditures. Germany, France, and the U.K backed by the increasing
demand for the technological advanced diagnostic devices account for the major
contributors to the European hemifacial spasm market.
The well-developed healthcare sector and the notable
pharmaceutical companies that are engaged in R&D activities for the
development of new drugs to treat hemifacial spasm are some of the key driving
forces pushing up the growth of the regional market. Additionally, government
support is fostering the market growth in the region, encouraging the market
players to develop effective therapeutics.
Whereas, the Asia Pacific hemifacial spasm market is
growing rapidly, emerging as a promising market, globally owing to the
introduction of new & advanced diagnostic options such as CT scan. The
rising demand for specialty healthcare services in emerging countries such as
India has fueled the growth of the regional market.
Also, factors such as the ever-increasing population
and the integration of advanced technologies in the healthcare sector are
propelling the growth of the regional market. Asian countries especially, India
and China provide immense growth opportunities for the hemifacial spasm market,
accounting for the considerable investment in R&D activities for prognostic
treatments and drug formulation.
Hemifacial Spasm Market – Competitive Analysis
Highly competitive, the hemifacial spasm market
appears to be widely expanded and fragmented characterized by several small and
large-scale companies operating the market. Matured players incorporate
strategic initiatives such as partnership, acquisition, collaboration, product
launch, and expansion, gaining a competitive advantage and thus maintaining
their positions in this market.
These players ensure their mission success, focusing
on optimizing situational awareness towards customers. They invest
substantially in the R&D and clinical trials to develop breakthrough
treatment procedures and drugs. To maximize their efficiency in the process and
operations, key players are focusing on developing a bettered method, a
diagnostic and treatment-response of the disease.
Industry/Innovation/ Related News:
February 01, 2019 --- Lupin Limited (India), a leading
global pharmaceutical company developing and delivering a wide range of branded
& generic formulations, biotechnology products and APIs launched its
revolutionary new drug - NaMuscla (mexiletine) to treat the symptomatic
treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in
Germany and the UK.
NaMuscla is approved across the European Union
for NDM disorders which are a group of rare, inherited neuromuscular conditions
in which myotonia, the inability to relax muscles following voluntary
contraction, is the most prominent clinical symptom. NaMuscla reduces myotonia
symptoms in adult patients, resulting in a significant improvement in patient
quality-of-life and other functional outcomes.
Major Players
Key players leading the global hemifacial spasm
market include Allergan, Inc., Abbott, Cephalon Inc., Ipsen Group,
GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merz Pharma GmbH and
Co. KGaA, Medytox, Inc., Novartis AG, Pfizer, ROCHE, Revance Therapeutics,
Inc., Sanofi S.A, Shire plc, UCB S.A., Stryker, Sunovion Pharmaceuticals, Inc.,
Valeant Pharmaceuticals International, Inc., and US WorldMeds, LLC.
Related News
About Market Research Future:
At Market Research Future (MRFR), we
enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by Components, Application, Logistics and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Comments
Post a Comment